How Immunotherapies at End of Life Affect Care Quality

View at publisher Summarise with VIRAT
Authors: Sarah DiGiulio
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Use of cytotoxic chemotherapy at the end of life is linked to poorer quality care, lower hospice use, and higher costs, prompting the National Quality Forum and ASCO to endorse a quality measure in 2012 limiting chemotherapy in the final 14 days of life. While use of cytotoxic agents has declined, studies show that end-of-life use of targeted therapies and immunotherapies has remained stable or increased, without clear survival benefit. “There was more use of these high-cost targeted therapies near the end of life, which are generally perceived as less toxic by oncologists, so that may explain why the exception was made,” explained Kerin B. Adelson, MD, Chief Quality Officer at MD Anderson Cancer Center, who was a coauthor on the aforementioned studies. However, their group wanted to look at whether these novel therapies are causing harm at the end of life. This led to a recent study from the researchers that looked at healthcare utilization at the end of life associated with use of novel anticancer therapies (JCO 2025; doi.org/10.1200/JCO-25-00530). Using a large sample from the SEER Medicare database of patients who received systemic anticancer therapy at the end of life, the research showed that use of all types of those therapies was associated with worse quality end-of-life care, including higher rates of hospitalizations and lower hospice use. “Each and every type of systemic anticancer therapy near the end of life led to higher rates of emergency room visits, hospitalizations, ICU use, medicalized death, and very, very significantly lower rates of hospice use,” Adelson said. These are important data that can help inform the conversations oncologists have with their patients as they approach the end of life, Adelson said. Study Details For the study, the researchers used the SEER Medicare database to identify 315,089 patients diagnosed with cancer between 2005 and 2019 who had died between 2015 and 2020. The sample included Medicare beneficiaries with a solid tumor diagnosis, including breast, colorectal, lung, prostate, bladder, cervical, kidney, liver, ovarian, pancreatic, melanoma, or uterine cancers. Only patients 66 or older with continuous Medicare fee-for-service Part A and B coverage for 12 months before death were included. This ensured availability of all end-of-life Medicare claims to allow the assessment of comorbidity. Additionally, only patients with Part D coverage within 30 days of death were included, ensuring accurate measurement of oral targeted therapies. The researchers grouped the patients according to use of systemic anticancer therapy within 30 days of death, based on inpatient or outpatient Medicare claims. The mutually exclusive categories were: cytotoxic chemotherapy only, immunotherapy only, targeted therapy only, combination cytotoxic chemotherapy and immunotherapy, combination cytotoxic chemotherapy and targeted therapy, other combination therapy, and no systemic anticancer therapy. They compared this end-of-life systemic anticancer therapy use with the following types of healthcare utilization in the last 30 days of life: emergency department visit, hospitalization, ICU admission, inpatient death, and use of hospice care. The results showed: 7.6% of patients received systemic anticancer therapy within 30 days of death. Patients who received any type of systemic anticancer therapy at the end of life were 3.2 times more likely to have one or more emergency department visits, 3.11 times more likely to be admitted to a hospital, 1.89 times more likely to be admitted to an ICU, and 2.31 times more likely to die in a hospital. Patients who received any type of systemic anticancer therapy at the end of life were 55% less likely to use hospice. All subtypes of systemic anticancer therapy were individually associated with higher healthcare utilization and lower hospice use. The results were stratified by cancer subtype, and then adjusted for age at death, sex, race, SEER staging, ZIP-code-level median income, and comorbidities. Conclusion Adelson said, “If we look at everything that happens to patients in their last month of life, we saw that those who receive systemic anticancer therapy are much more likely to have each of these acute care markers: they're more likely to go to the hospital, they're more likely to go to the emergency department, they're more likely to go to the emergency department more than once, and they're more likely to die in the hospital. They're also less likely to go to hospice.” Across the board, use of all therapy types was linked to this higher utilization of healthcare services, explained coauthor Maureen E. Canavan, PhD, MPH, Associate Research Scientist at the Cancer Outcomes Public Policy and Effectiveness Research Center at Yale University School of Medicine. “There was consistently this higher constellation of care present regardless of the treatment patients are getting.” This is a key takeaway and a discussion point oncologists can use with their patients, Canavan said. The researchers note a similar trend was found in another study in a population of Canadian patients. Use of novel systemic anticancer therapy at end of life was linked to higher incidence of health services use and hospital deaths (JCO 2025; doi.org/10.1200/JCO-24-02816). In their conclusion, the researchers note these two takeaways, supported by research that oncologists can share with patients approaching the end of life. More treatment is not associated with improved survival. Continuation of therapy is associated with a more medicalized death. The research team hopes that this study and future research could lead to revising the NQF guideline further to extend the timeline from 14 to 30 days when it comes to the window of time before death linked to more harm to a patient from receiving systemic anticancer therapy. “There's more of an opportunity to provide less harm with that timeline,” Canavan said. Sarah DiGiulio is a contributing writer.

Fields of Study & Subjects

Palliative Care and End-of-Life Issues Palliative and Oncologic Care Pain Management and Opioid Use

Publication details

Journal / source
Oncology Times
Volume
48
Issue
4
Pages
24–24
Publication date
27 March 2026
Language
EN